Free weekly newsletter
Get the free weekly contract digest
The new new contracts, who’s behind them, and what they mean — delivered to your inbox every week. No credit card, unsubscribe anytime.
Weekly Digest
New new contracts, summarized for you
Straight to Inbox
No login, no app to check — it comes to you
Contract Trends
See who's moving and how much in your market
No credit card required Weekly contract digest
NLS Pharmaceutics and Kadimastem Announce Initial Closing of $500,000 Fundraising Effort for Merger
Jan 08, 2025•over 1 year ago
Contract Type
partnership
ZurichManufacturingBiotechnologyHealthcareHealth CareTherapeuticsDescription
NLS Pharmaceutics Ltd. and Kadimastem Ltd. have announced the initial closing of a $500,000 fundraising initiative, marking the first step in a larger $1 million fundraising round to facilitate a proposed merger between the two companies. The merger aims to create a Nasdaq-traded biotechnology company with advanced-stage product candidates, significantly strengthening their strategic position in the biotechnology sector
Related People
Suggested for you
Agreement Insights
Based on industry dataStrategic partnership established
Partnership agreements typically involve technology integration and joint go-to-market strategies
Contract momentum indicator
Companies with recent agreements are 2.3x more likely to make additional purchases within 6 months